This systematic review evaluates the roles of interleukin-6 (IL-6) and interleukin-1β (IL-1β) in cardiovascular diseases (CVDs). IL-6 and IL-1β are critical inflammatory cytokines implicated in CVD progression. The review synthesizes data from 12 studies published between 2014 and 2024, covering various CVDs such as peripheral artery disease (PAD), myocardial infarction, heart failure, and coronary artery disease. Elevated levels of IL-6 and IL-1β were significantly associated with adverse cardiovascular outcomes, including increased risk of myocardial infarction, heart failure, and overall mortality. Meta-analyses confirmed a significant association between higher levels of IL-6 and IL-1β and increased risk of adverse cardiovascular events. These findings suggest that targeting IL-6 and IL-1β could offer promising therapeutic strategies to reduce inflammation and improve cardiovascular outcomes. The review highlights the importance of personalized medicine approaches, where treatments are tailored based on individual patient profiles and inflammatory status, to enhance the efficacy of anti-inflammatory therapies.This systematic review evaluates the roles of interleukin-6 (IL-6) and interleukin-1β (IL-1β) in cardiovascular diseases (CVDs). IL-6 and IL-1β are critical inflammatory cytokines implicated in CVD progression. The review synthesizes data from 12 studies published between 2014 and 2024, covering various CVDs such as peripheral artery disease (PAD), myocardial infarction, heart failure, and coronary artery disease. Elevated levels of IL-6 and IL-1β were significantly associated with adverse cardiovascular outcomes, including increased risk of myocardial infarction, heart failure, and overall mortality. Meta-analyses confirmed a significant association between higher levels of IL-6 and IL-1β and increased risk of adverse cardiovascular events. These findings suggest that targeting IL-6 and IL-1β could offer promising therapeutic strategies to reduce inflammation and improve cardiovascular outcomes. The review highlights the importance of personalized medicine approaches, where treatments are tailored based on individual patient profiles and inflammatory status, to enhance the efficacy of anti-inflammatory therapies.